BCL2 and breast carcinoma: The compound, as an adjuvant, downregulates the expression of the ABC transporter and resultantly promotes the uptake of an anticancer agent, which then results in reduced levels of anti-apoptotic proteins such as survivin, Bcl-2, and Bcl-xL and increased levels of activated caspase 9, thus promoting the breast cancer cells’ apoptotic death [110,111].